In summary, these computer-assisted approaches enable a rapid <strong>and</strong> easy identification of CTL epitopes that can be included in the proposed CTL-inducing vaccine <strong>and</strong> will help the selection of epitope flanking spacers that improve proteasome-mediated epitope processing. The existing proteasome cleavage programs are currently being tested for general applicability, where<strong>by</strong> the availability of new cleavage data obtained through in vitro digestion of designed constructs with purified proteasomes in turn will allow the designers to improve their programs. References 1 Kloetzel, P.-M. (2001) Nat Rev Mol Cell Biol 2: 179±187. 2 Pamer, E. <strong>and</strong> Cresswell, P. (1998) Annu Rev Immunol 16: 323±358. 3 Coux, O., Tanaka, K. <strong>and</strong> Goldberg, A. L. (1996) Annu Rev Biochem 65: 801± 847. 4 Coffino, P. (2001) Nat Rev Mol Cell Biol 2: 188±194. 5 Groll, M., Ditzel, L., Læwe, J., et al. (1997) Nature 386: 463±471. 6 Bochtler, M. Ditzel, L., Groll, M., Hartmann, C. <strong>and</strong> Huber, R (1999) Annu Rev Biophys Biomol Struct 28: 295±317. 7 Braun, B. C.,Glickman, M., Kraft, R., Dahlmann, B., Kloetzel, P.-M., Finley, D. <strong>and</strong> Schmidt, M. (1999) Nat Cell Biol 1: 221±226. 8 Strickl<strong>and</strong>, E., Hakala, K., Thomas, P. J. <strong>and</strong> DeMartino, G. N. (2000) J Biol Chem. 275: 5565±5572. 9 Dubiel,W., Pratt, G., Ferrell, K. <strong>and</strong> Rechsteiner, M. (1992) J Biol Chem 267: 22369±22377. 10 Ma, C. P., Slaughter, C. A. <strong>and</strong> De- Martino, G. N. (1992) J Biol Chem 267: 10515±23. 11 Knowlton, J. R., Johnston, S. C., Whit<strong>by</strong>, F. G., Realini, C., Zhang, Z., Rechsteiner, M. <strong>and</strong> Hill, C. P. (1997) Nature 390: 639±643. 12 Griffin, T. A., N<strong>and</strong>i, D., Cruz, M., Fehling, H. J.,Van Kaer, L., Monaco, J. J. <strong>and</strong> Colbert, R. A. (1998) JExp Med 187: 97±104. 13 Groettrup, M., St<strong>and</strong>era, S., Stohwasser, R. <strong>and</strong> Kloetzel, P.-M. (1997) Proc Natl Acad Sci USA 94: 8970±8975. References 14 Schmidt, M. <strong>and</strong> Kloetzel, P.-M. (1997) FASEB J 11: 1235±1243. 15 N<strong>and</strong>i, D.,Woodward, E., Ginsburg, D. B. <strong>and</strong> Monaco J. J. (1997) EMBO J 16: 5363±5375. 16 Eleuteri, A. M., Kohanski, R. A., Cardozo, C. <strong>and</strong> Orlowski, M. (1997) J Biol Chem 272: 11824±11831. 17 Boes, B., Hengel, H., Ruppert, T., Multhaup, G., Koszinowski, U. H. <strong>and</strong> Kloetzel, P.-M. (1994) J Exp Med 179: 901±909. 18 Driscoll, J., Brown, M. G., Finley, D. <strong>and</strong> Monaco, J. J. (1993) Nature 365: 262±264. 19 Gaczynska, M., Rock, K. L. <strong>and</strong> Goldberg, A. L. (1993) Nature 365: 264±267. 20 Ustrell,V., Pratt, G. <strong>and</strong> Rechsteiner, M. (1995) Proc Natl Acad Sci USA 92: 584±588. 21 Groettrup, M., Ruppert,T., Kuehn, L., Seeger, M., St<strong>and</strong>era, S., Koszinowski, U. <strong>and</strong> Kloetzel, P.-M. (1995) J Biol Chem 270: 23808±23815. 22 Nussbaum, A. K., Dick, T. P., Keilholz,W., Schirle, M., Stevanovic, S., Dietz, K., Heinemeyer,W., Groll, M., Wolf, D. H., Huber, R., Rammensee, H. G. <strong>and</strong> Schild, H. (1998) Proc Natl Acad Sci USA 95: 12504±12509. 23 Salzmann, U., Kral, S., Braun, B., St<strong>and</strong>era, S., Schmidt, M., Kloetzel, P. M. <strong>and</strong> Sijts, A. (1999) FEBS Lett 454: 11±15. 24 Arnold, D., Driscoll, J., Androlewicz, M., Hughes, E., Cresswell, P. <strong>and</strong> Spies, T. (1993) Nature 360: 171± 174. 25 Momburg, F., Ortiz-Navarrete,V., Neefjes, J., Goulmy, E., van-de-Wal,Y., 37
38 3 Processing <strong>and</strong> Presentation of Tumor-associated Antigens Spits, H., Powis, S. J., Butcher, G. W., Howard, J. C.,<strong>Walden</strong>, P. <strong>and</strong> Haemmerling, G. (1993) Nature 360: 174± 177. 26 Yewdell, J., Lapham, C., Bacik, I., Spies, T. <strong>and</strong> Bennink, J. (1994) JImmunol 152: 1163±1170. 27 Cerundolo,V., Kelly, A., Elliot, T., Trowsdale, J. <strong>and</strong> Townsend, A. (1995) Eur J Immunol 25: 554±562. 28 Sijts, A. J., Ruppert, T., Rehermann, B., Schmidt, M., Koszinowski, U. <strong>and</strong> Kloetzel, P.-M. (2000) J Exp Med 191: 503±514. 29 Sijts, A. J., St<strong>and</strong>era, S., Toes, R. E., Ruppert, T., Beekman, N. J., van Veelen, P. A., Ossendorp, F. A., Melief, C. J. <strong>and</strong> Kloetzel, P.-M. (2000) JImmunol 164: 4500±4506. 30 Schwarz, K.,Van Den Broek, M., Kostka, S., Kraft, R., Soza, A., Schmidtke, G., Kloetzel, P.-M. <strong>and</strong> Groettrup, M. (2000) J Immunol 165: 768±778. 31 van Hall, T., Sijts, A., Camps, M., Offringa, R., Melief, C., Kloetzel, P.-M. <strong>and</strong> Ossendorp, F. (2000) J Exp Med 192: 483±494. 32 Morel, S., Levy, F., Burlet-Schiltz, O., Brasseur, F., Probst-Kepper, M., Peitrequin, A. L., Monsarrat, B.,Van Velthoven, R., Cerottini, J. C., Boon, T., Gairin, J. E. <strong>and</strong> Van den Eynde, B. J. (2000) Immunity 12: 107±117. 33 Sun,Y., Sijts, A. et al. (2002) <strong>Cancer</strong> Res. 62, 2875±2882. 34 Zhang, Z., Krutchinsky, A., Endicott, S., Realini, C., Rechsteiner, M. <strong>and</strong> St<strong>and</strong>ing, K. G. (1999) Biochemistry 38: 5651±5658. 35 Hendil, K. B., Khan, S. <strong>and</strong> Tanaka, K. (1998) Biochem J 332: 749±754. 36 Jiang, H. <strong>and</strong> Monaco, J. J. (1997) Immunogenetics 46: 93±98. 37 Preckel,T., Fung-Leung,W. P., Cai, Z., Vitiello, A., Salter-Cid, L., Winqvist, O.,Wolfe, T. G.,Von Herrath, M., Angulo, A., Ghazal, P., Lee, J. D., Fourie, A. M.,Wu,Y., Pang, J., Ngo, K., Peterson, P. A., Fruh, K. <strong>and</strong> Yang,Y. (1999) Science 286: 2162±2165. 38 Macagno, A., Gilliet, M., Sallusto, F., Lanzavecchia, A., Nestle, F. O. <strong>and</strong> Groettrup, M. (1999) Eur J Immunol 29: 4037±4042. 39 Chu-Ping, M., Slaughter, C. A. <strong>and</strong> DeMartino, G. N. (1992) Biochim Biophys Acta 1119: 303±311. 40 McCutchen-Maloney, S. L., Matsuda, K., Shimbara, N., Binns, D. D., Tanaka, K., Slaughter, C. A. <strong>and</strong> De- Martino, G. N. (2000) J Biol Chem 275: 18557±18565. 41 Zaiss, D. M., St<strong>and</strong>era, S., Holzhutter, H., Kloetzel, P. <strong>and</strong> Sijts, A. J. (1999) FEBS Lett 457: 333±338. 42 Groettrup, M., Soza, A., Eggers, M., Kuehn, L., Dick, T. P., Schild, H., Rammensee, H. G., Koszinowski, U. H. <strong>and</strong> Kloetzel, P.-M. (1996) Nature 381: 166±168. 43 Whit<strong>by</strong>, F. G., Masters, E. I., Kramer, L., Knowlton, J. R.,Yao,Y.,Wang, C. C. <strong>and</strong> Hill, C. P. (2000) Nature 408: 115± 120. 44 Dick, T. P., Ruppert, T., Groettrup, M., Kloetzel, P. M., Kuehn, L., Koszinowski, U. H., Stevanovic, S., Schild, H. <strong>and</strong> Rammensee, H. G. (1996) Cell 86: 253±262. 45 Li, J., Gao, X., Ortega, J., Nazif, T., Joss, L., Bogyo, M., Steven, A. C. <strong>and</strong> Rechsteiner, M. (2001) EMBO J 20: 3359±3369. 46 Seliger, B., Hohne, A., Knuth, A., Bernhard, H., Meyer, T., Tampe, R., Momburg, F. <strong>and</strong> Huber, C. (1996) <strong>Cancer</strong> Res 56: 1756±1760. 47 Kageshita, T., Hirai, S., Ono, T., Hicklin, D. J. <strong>and</strong> Ferrone, S. (1999) Am J Pathol 154: 745±754. 48 Seliger, B.,Wollscheid, U., Momburg, F., Blankenstein, T. <strong>and</strong> Huber, C. (2001) <strong>Cancer</strong> Res 61: 1095±1099. 49 Rotem-Yehudar, R., Groettrup, M., Soza, A., Kloetzel, P.-M. <strong>and</strong> Ehrlich, R. (1996) J Exp Med 183: 499± 514. 50 Kessler, J. H., Beekman, N. J., Bres- Vloemans, S. A.,Verdijk, P., van Veelen, P. A., Kloosterman-Joosten, A. M.,Vissers, D. C., ten Bosch, G. J., Kester, M. G., Sijts, A., Drijfhout, J. W., Ossendorp, F., Offringa, R. <strong>and</strong> Melief, C. J. (2001) J Exp Med 193: 73± 88.
- Page 1 and 2:
Cancer Immune Therapie: Current and
- Page 3 and 4:
Editors: Dr. Gernot Stuhler Univers
- Page 5 and 6:
VI Preface Recent years have seen a
- Page 7 and 8:
VIII Contents 2.5.3 Antigens Encode
- Page 9 and 10:
X Contents 6.4.2 Natural Killer (NK
- Page 11 and 12:
XII Contents 9.6 Loading DC with An
- Page 13 and 14:
XIV Contents 14.2.2.1 Cancer-specif
- Page 15 and 16:
List of Contributors Richard Bucala
- Page 17 and 18:
Color Plates Fig. 5.2 The MHC class
- Page 19 and 20:
Fig. 5.5 Different immune effector
- Page 21 and 22:
Fig. 5.17 Possible pathway for the
- Page 23 and 24: Fig. 6.2 T lymphocytes in the tumor
- Page 25 and 26: Index a acidic and basic fibroblast
- Page 27 and 28: ±, see also tumors cationic lipids
- Page 29 and 30: e EBV see Epstein-Barr virus EDR se
- Page 31 and 32: immature Mo-DCs 184 immune cells ±
- Page 33 and 34: MHC class I antigen-processing mach
- Page 35 and 36: ±, onco- 209 ±, over-expressed ce
- Page 37 and 38: TICD see tumor-induced cell death T
- Page 39 and 40: Part 1 Tumor Antigenicity Cancer Im
- Page 41 and 42: 4 1 Search for Universal Tumor-Asso
- Page 43 and 44: 6 1 Search for Universal Tumor-Asso
- Page 45 and 46: 8 1 Search for Universal Tumor-Asso
- Page 47 and 48: 10 1 Search for Universal Tumor-Ass
- Page 49 and 50: 12 1 Search for Universal Tumor-Ass
- Page 51 and 52: 14 1 Search for Universal Tumor-Ass
- Page 53 and 54: 16 1 Search for Universal Tumor-Ass
- Page 55 and 56: 18 2 Serological Determinants On Tu
- Page 57 and 58: 20 2 Serological Determinants On Tu
- Page 59 and 60: 22 2 Serological Determinants On Tu
- Page 61 and 62: 24 2 Serological Determinants On Tu
- Page 63 and 64: 26 2 Serological Determinants On Tu
- Page 65 and 66: 28 2 Serological Determinants On Tu
- Page 67 and 68: 30 Cancer Immune Therapie: Current
- Page 69 and 70: 32 3 Processing and Presentation of
- Page 71 and 72: 34 3 Processing and Presentation of
- Page 73: 36 3 Processing and Presentation of
- Page 77 and 78: 40 Cancer Immune Therapie: Current
- Page 79 and 80: 42 4 T Cells In Tumor Immunity cult
- Page 81 and 82: 44 4 T Cells In Tumor Immunity cell
- Page 83 and 84: 46 4 T Cells In Tumor Immunity to T
- Page 85 and 86: 48 4 T Cells In Tumor Immunity Alth
- Page 87 and 88: 50 4 T Cells In Tumor Immunity Tab.
- Page 89 and 90: 52 4 T Cells In Tumor Immunity rest
- Page 91 and 92: 54 4 T Cells In Tumor Immunity 53 T
- Page 93 and 94: Part 2 Immune Evasion and Suppressi
- Page 95 and 96: 60 5 Major Histocompatibility Compl
- Page 97 and 98: 62 5 Major Histocompatibility Compl
- Page 99 and 100: 64 5 Major Histocompatibility Compl
- Page 101 and 102: 66 5 Major Histocompatibility Compl
- Page 103 and 104: 68 Tab. 5.1 HLA class I loss attrib
- Page 105 and 106: 70 5 Major Histocompatibility Compl
- Page 107 and 108: 72 5 Major Histocompatibility Compl
- Page 109 and 110: 74 5 Major Histocompatibility Compl
- Page 111 and 112: 76 5 Major Histocompatibility Compl
- Page 113 and 114: 78 5 Major Histocompatibility Compl
- Page 115 and 116: 80 5 Major Histocompatibility Compl
- Page 117 and 118: 82 5 Major Histocompatibility Compl
- Page 119 and 120: 84 5 Major Histocompatibility Compl
- Page 121 and 122: 86 5 Major Histocompatibility Compl
- Page 123 and 124: 88 5 Major Histocompatibility Compl
- Page 125 and 126:
90 5 Major Histocompatibility Compl
- Page 127 and 128:
92 5 Major Histocompatibility Compl
- Page 129 and 130:
94 5 Major Histocompatibility Compl
- Page 131 and 132:
96 6 Immune Cells in the Tumor Micr
- Page 133 and 134:
98 6 Immune Cells in the Tumor Micr
- Page 135 and 136:
100 6 Immune Cells in the Tumor Mic
- Page 137 and 138:
102 6 Immune Cells in the Tumor Mic
- Page 139 and 140:
104 6 Immune Cells in the Tumor Mic
- Page 141 and 142:
106 6 Immune Cells in the Tumor Mic
- Page 143 and 144:
108 6 Immune Cells in the Tumor Mic
- Page 145 and 146:
110 6 Immune Cells in the Tumor Mic
- Page 147 and 148:
112 6 Immune Cells in the Tumor Mic
- Page 149 and 150:
114 6 Immune Cells in the Tumor Mic
- Page 151 and 152:
116 6 Immune Cells in the Tumor Mic
- Page 153 and 154:
118 6 Immune Cells in the Tumor Mic
- Page 155 and 156:
Tab. 7.1 Effects of tumor-derived m
- Page 157 and 158:
122 7 Immunosuppresive Factors in C
- Page 159 and 160:
124 7 Immunosuppresive Factors in C
- Page 161 and 162:
126 7 Immunosuppresive Factors in C
- Page 163 and 164:
128 7 Immunosuppresive Factors in C
- Page 165 and 166:
130 7 Immunosuppresive Factors in C
- Page 167 and 168:
132 7 Immunosuppresive Factors in C
- Page 169 and 170:
134 7 Immunosuppresive Factors in C
- Page 171 and 172:
136 7 Immunosuppresive Factors in C
- Page 173 and 174:
138 7 Immunosuppresive Factors in C
- Page 175 and 176:
140 7 Immunosuppresive Factors in C
- Page 177 and 178:
142 7 Immunosuppresive Factors in C
- Page 179 and 180:
144 7 Immunosuppresive Factors in C
- Page 181 and 182:
146 7 Immunosuppresive Factors in C
- Page 183 and 184:
148 7 Immunosuppresive Factors in C
- Page 185 and 186:
150 7 Immunosuppresive Factors in C
- Page 187 and 188:
152 7 Immunosuppresive Factors in C
- Page 189 and 190:
154 7 Immunosuppresive Factors in C
- Page 191 and 192:
156 8 Interleukin-10 in Cancer Immu
- Page 193 and 194:
158 8 Interleukin-10 in Cancer Immu
- Page 195 and 196:
160 8 Interleukin-10 in Cancer Immu
- Page 197 and 198:
162 8 Interleukin-10 in Cancer Immu
- Page 199 and 200:
164 8 Interleukin-10 in Cancer Immu
- Page 201 and 202:
166 8 Interleukin-10 in Cancer Immu
- Page 203 and 204:
168 8 Interleukin-10 in Cancer Immu
- Page 205 and 206:
170 8 Interleukin-10 in Cancer Immu
- Page 207 and 208:
172 8 Interleukin-10 in Cancer Immu
- Page 209 and 210:
174 8 Interleukin-10 in Cancer Immu
- Page 211 and 212:
Part 3 Strategies for Cancer Immuno
- Page 213 and 214:
180 9 Dendritic Cells and Cancer: P
- Page 215 and 216:
182 9 Dendritic Cells and Cancer: P
- Page 217 and 218:
184 9 Dendritic Cells and Cancer: P
- Page 219 and 220:
186 9 Dendritic Cells and Cancer: P
- Page 221 and 222:
188 9 Dendritic Cells and Cancer: P
- Page 223 and 224:
190 9 Dendritic Cells and Cancer: P
- Page 225 and 226:
192 9 Dendritic Cells and Cancer: P
- Page 227 and 228:
194 9 Dendritic Cells and Cancer: P
- Page 229 and 230:
196 9 Dendritic Cells and Cancer: P
- Page 231 and 232:
198 9 Dendritic Cells and Cancer: P
- Page 233 and 234:
200 9 Dendritic Cells and Cancer: P
- Page 235 and 236:
202 9 Dendritic Cells and Cancer: P
- Page 237 and 238:
204 Cancer Immune Therapie: Current
- Page 239 and 240:
206 10 The Immune System in Cancer:
- Page 241 and 242:
208 10 The Immune System in Cancer:
- Page 243 and 244:
210 10 The Immune System in Cancer:
- Page 245 and 246:
212 10 The Immune System in Cancer:
- Page 247 and 248:
214 10 The Immune System in Cancer:
- Page 249 and 250:
216 10 The Immune System in Cancer:
- Page 251 and 252:
218 10 The Immune System in Cancer:
- Page 253 and 254:
220 10 The Immune System in Cancer:
- Page 255 and 256:
222 10 The Immune System in Cancer:
- Page 257 and 258:
224 10 The Immune System in Cancer:
- Page 259 and 260:
226 10 The Immune System in Cancer:
- Page 261 and 262:
228 10 The Immune System in Cancer:
- Page 263 and 264:
230 Cancer Immune Therapie: Current
- Page 265 and 266:
232 11 Hybrid Cell Vaccination for
- Page 267 and 268:
234 11 Hybrid Cell Vaccination for
- Page 269 and 270:
236 11 Hybrid Cell Vaccination for
- Page 271 and 272:
238 11 Hybrid Cell Vaccination for
- Page 273 and 274:
240 11 Hybrid Cell Vaccination for
- Page 275 and 276:
242 11 Hybrid Cell Vaccination for
- Page 277 and 278:
244 11 Hybrid Cell Vaccination for
- Page 279 and 280:
246 11 Hybrid Cell Vaccination for
- Page 281 and 282:
248 11 Hybrid Cell Vaccination for
- Page 283 and 284:
250 11 Hybrid Cell Vaccination for
- Page 285 and 286:
252 11 Hybrid Cell Vaccination for
- Page 287 and 288:
254 12 Principles and Strategies Em
- Page 289 and 290:
256 12 Principles and Strategies Em
- Page 291 and 292:
258 12 Principles and Strategies Em
- Page 293 and 294:
260 12 Principles and Strategies Em
- Page 295 and 296:
262 12 Principles and Strategies Em
- Page 297 and 298:
264 12 Principles and Strategies Em
- Page 299 and 300:
266 12 Principles and Strategies Em
- Page 301 and 302:
268 Cancer Immune Therapie: Current
- Page 303 and 304:
270 13 Applications of CpG Motifs f
- Page 305 and 306:
272 13 Applications of CpG Motifs f
- Page 307 and 308:
274 13 Applications of CpG Motifs f
- Page 309 and 310:
276 13 Applications of CpG Motifs f
- Page 311 and 312:
278 13 Applications of CpG Motifs f
- Page 313 and 314:
280 13 Applications of CpG Motifs f
- Page 315 and 316:
282 13 Applications of CpG Motifs f
- Page 317 and 318:
284 13 Applications of CpG Motifs f
- Page 319 and 320:
286 13 Applications of CpG Motifs f
- Page 321 and 322:
288 14 The T-Body Approach: Towards
- Page 323 and 324:
290 14 The T-Body Approach: Towards
- Page 325 and 326:
292 14 The T-Body Approach: Towards
- Page 327 and 328:
294 14 The T-Body Approach: Towards
- Page 329 and 330:
296 14 The T-Body Approach: Towards
- Page 331 and 332:
298 14 The T-Body Approach: Towards
- Page 333 and 334:
300 15 Bone Marrow Transplantation
- Page 335 and 336:
302 15 Bone Marrow Transplantation
- Page 337 and 338:
304 15 Bone Marrow Transplantation
- Page 339 and 340:
306 15 Bone Marrow Transplantation
- Page 341 and 342:
308 15 Bone Marrow Transplantation
- Page 343 and 344:
310 15 Bone Marrow Transplantation
- Page 345 and 346:
312 16 Immunocytokines: Versatile M
- Page 347 and 348:
314 16 Immunocytokines: Versatile M
- Page 349 and 350:
316 16 Immunocytokines: Versatile M
- Page 351 and 352:
318 16 Immunocytokines: Versatile M
- Page 353 and 354:
320 16 Immunocytokines: Versatile M
- Page 355 and 356:
322 16 Immunocytokines: Versatile M
- Page 357 and 358:
324 16 Immunocytokines: Versatile M
- Page 359 and 360:
326 16 Immunocytokines: Versatile M
- Page 361 and 362:
328 16 Immunocytokines: Versatile M
- Page 363 and 364:
330 16 Immunocytokines: Versatile M
- Page 365 and 366:
332 16 Immunocytokines: Versatile M
- Page 367 and 368:
334 16 Immunocytokines: Versatile M
- Page 369 and 370:
336 16 Immunocytokines: Versatile M
- Page 371 and 372:
338 16 Immunocytokines: Versatile M
- Page 373 and 374:
340 16 Immunocytokines: Versatile M
- Page 375 and 376:
342 16 Immunocytokines: Versatile M
- Page 377 and 378:
344 16 Immunocytokines: Versatile M
- Page 379 and 380:
346 16 Immunocytokines: Versatile M
- Page 381 and 382:
348 17 Immunotoxins and Recombinant
- Page 383 and 384:
350 17 Immunotoxins and Recombinant
- Page 385 and 386:
352 17 Immunotoxins and Recombinant
- Page 387 and 388:
354 17 Immunotoxins and Recombinant
- Page 389 and 390:
356 17 Immunotoxins and Recombinant
- Page 391 and 392:
358 17 Immunotoxins and Recombinant
- Page 393 and 394:
360 17 Immunotoxins and Recombinant
- Page 395 and 396:
362 17 Immunotoxins and Recombinant
- Page 397 and 398:
364 17 Immunotoxins and Recombinant
- Page 399 and 400:
366 17 Immunotoxins and Recombinant
- Page 401 and 402:
368 17 Immunotoxins and Recombinant
- Page 403 and 404:
370 17 Immunotoxins and Recombinant
- Page 405 and 406:
372 17 Immunotoxins and Recombinant
- Page 407 and 408:
374 17 Immunotoxins and Recombinant
- Page 409 and 410:
376 17 Immunotoxins and Recombinant
- Page 411 and 412:
378 17 Immunotoxins and Recombinant
- Page 413 and 414:
380 Cancer Immune Therapie: Current
- Page 415 and 416:
382 Glossary tion to the variable d
- Page 417 and 418:
384 Glossary suppressor gene produc
- Page 419 and 420:
386 Glossary press the proper recep
- Page 421 and 422:
388 Glossary gp96 See Chaperone. Gr
- Page 423 and 424:
390 Glossary cytes and addressing l
- Page 425 and 426:
392 Glossary T bodies are being tes